

SUSTAINABILITY REPORT

2023 / 2024

We proudly announce our 6th Sustainability Report.
This report has been drafted in accordance with the updated Standards of the Global Reporting Initiative (GRI), and the United Nations Sustainable Goals.
It shows the key achievements that consolidate our commitment towards innovation, quality and economic, social and environmental sustainability

● A decade reporting our progress on our ESG Report*



Governance

Ethical leadership and long-term vision



+30 years of experience
Launch *Nuestra Fórmula*



Board survival and second-generation incorporation



Strategy based on sustainability and international expansion



Code of Ethics implemented in all operations

Industrial Capital

International Standard Productivity

2 industrial complexes



production of + 70.000 soft gel capsules per hour

Annual production capacity of + 80 M units



Production of sterile oncological medicines under the strictest industrial standards + EMA + Annex 1 EU



3 business units:



SAVANT
General Medicines
South Cone: Argentina, Chile, Uruguay, Paraguay and Bolivia



VIVUNT
OTC Medicines
USA Trademarks NOTTS & AXIV
Commercialization: off & online



VIVUNT
Oncology
Europe
DMO Agreements

37 own brands

Corporate Stock

Culture and community



218 collaborators



45% women



+14 eNPS points



23 average hours of training per person



100% performance of assessed teams



+10 initiatives focused on health and education



Environmental Capital

Sustainable Operation and power efficiency



Certification of maximum power efficiency
Industrial Complex in Spain



Water management and liquid effluents' treatment
certification at both industrial complexes



Sustained progress
► -19% power consumption
► -4% water consumption at CIA



Learn more

from our Sustainability Report

VIRIXENE

*Environmental, Social, and Governance.